IPSC — Century Therapeutics Share Price
Last trade - 00:00- $200.29m
- $27.55m
- $2.24m
- 22
- 15
- 80
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.08 | ||
| Price to Tang. Book | 1.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 89.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -42.74% | ||
| Return on Equity | -56.07% | ||
| Operating Margin | -6556.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 5.2 | 2.23 | 6.01 | 19.77 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.
Directors
- Joseph Jimenez NEC (61)
- Osvaldo Flores PRE (58)
- Hyam Levitsky CEX (63)
- Adrienne Farid COO (59)
- Gregory Russotti CTO (54)
- Luis Borges CSO (59)
- Michael Diem OTH (52)
- Toshikazu Ban IND (60)
- Kimberly Blackwell IND (52)
- Cynthia Butitta IND (66)
- Eli Casdin IND (48)
- Juerg Eckhardt IND (54)
- Alessandro Riva IND (60)
- Carlo Rizzuto IND (51)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 5th, 2018
- Public Since
- June 17th, 2021
- No. of Shareholders
- 117
- No. of Employees
- 152
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 64,817,863
- Address
- 25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA, 19104
- Web
- https://www.centurytx.com/
- Phone
- +1 2159814000
- Auditors
- Ernst & Young LLP
Similar to IPSC
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:05 UTC, shares in Century Therapeutics are trading at $3.09. This share price information is delayed by 15 minutes.
Shares in Century Therapeutics last closed at $3.09 and the price had moved by -0.32% over the past 365 days. In terms of relative price strength the Century Therapeutics share price has underperformed the S&P500 Index by -17.05% over the past year.
The overall consensus recommendation for Century Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Century Therapeutics does not currently pay a dividend.
Century Therapeutics does not currently pay a dividend.
Century Therapeutics does not currently pay a dividend.
To buy shares in Century Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.09, shares in Century Therapeutics had a market capitalisation of $200.29m.
Here are the trading details for Century Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IPSC
Based on an overall assessment of its quality, value and momentum Century Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Century Therapeutics is $14.83. That is 379.94% above the last closing price of $3.09.
Analysts covering Century Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.05 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Century Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +77.25%.
As of the last closing price of $3.09, shares in Century Therapeutics were trading +5.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Century Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Century Therapeutics' management team is headed by:
- Joseph Jimenez - NEC
- Osvaldo Flores - PRE
- Hyam Levitsky - CEX
- Adrienne Farid - COO
- Gregory Russotti - CTO
- Luis Borges - CSO
- Michael Diem - OTH
- Toshikazu Ban - IND
- Kimberly Blackwell - IND
- Cynthia Butitta - IND
- Eli Casdin - IND
- Juerg Eckhardt - IND
- Alessandro Riva - IND
- Carlo Rizzuto - IND